Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.
Gilead has successfully convinced a panel of arbitrators that competitor Roche has no legitimate claims on Sovaldi, its hep C blockbuster.
Biogen Idec's multibillion-selling multiple sclerosis drug Tecfidera is grabbing market share left and right, but Denmark's Forward Pharma says it has a plan to take on the monster seller with its own product.
Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until at least mid-2016. But now, it's filed another, wider suit.
Teva just won't give up on delaying generic Copaxone. Its latest tactic: filing a citizen petition with the FDA to once again push for full-scale, placebo-controlled clinical trials for all copies of its multiple sclerosis med.
Pfizer's patent for erectile dysfunction drug Viagra goes off patent in China next month and drugmakers are lining up to produce cheap versions of the little blue pill.
Roche and Cipla are writing a new chapter in the bitter battles that have been fought by Western drugmakers over their patents in India. They are in mediation over the patent for Roche's blockbuster cancer fighter Tarceva, in what may be the first case to take this route.
Weak Qsymia sales have been the all-important issue for Vivus since the highly anticipated obesity therapy stumbled out of the gate, inspiring an all-out proxy war that wreaked havoc on the company's boardroom. And the California company isn't about to cede what market share it does have to Actavis--at least, not without a fight.
As Allergan tries to fend off Valeant's hostile advances, it's been touting its sales prospects as a standalone company. But with a Tuesday court ruling invalidating patents on its eyelash growth drug Latisse, its top-line potential could shrink a little down the line.
Eli Lilly lost a patent fight with Actavis in English High Court, in a ruling that paves the way for copycat competition not only in that country, but several others in Europe.